User profiles for Ulrike Lorch

Ulrike Lorch

Medical Director, Richmond Pharmacology
Verified email at richmondpharmacology.com
Cited by 1170

[HTML][HTML] Time-and race-specific haematological reference intervals for healthy volunteer trials: a retrospective analysis of pooled data from multiple phase I trials

…, S Fernandes, D Djumanov, U Lorch… - Frontiers in …, 2020 - frontiersin.org
Most UK hospitals, laboratories, and research institutions use uniform reference intervals (RI)
that do not take into account known diurnal and racial variation in total white blood cells (…

Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study

…, L Rode, H Weigt, C Genschel, U Lorch… - European heart …, 2021 - academic.oup.com
Aims Cardiac microRNA-132-3p (miR-132) levels are increased in patients with heart
failure (HF) and mechanistically drive cardiac remodelling processes. CDR132L, a specific …

Insulin at normal physiological levels does not prolong QTc interval in thorough QT studies performed in healthy volunteers

J Taubel, U Lorch, G Ferber, J Singh… - British journal of …, 2013 - Wiley Online Library
Aims Food is known to shorten the QT c ( QT c I and QT c F ) interval and has been proposed
as a non‐pharmacological method of confirming assay sensitivity in thorough QT ( TQT ) …

[HTML][HTML] The power of phase I studies to detect clinical relevant QTc prolongation: a resampling simulation study

G Ferber, U Lorch, J Täubel - BioMed Research International, 2015 - hindawi.com
Concentration-effect (CE) models applied to early clinical QT data from healthy subjects are
described in the latest E14 Q&A document as promising analysis to characterise QTc …

Lamotrigine does not prolong QTc in a thorough QT/QTc study in healthy subjects

…, JG Wright, K Maltby, U Lorch… - British journal of …, 2008 - Wiley Online Library
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • Drugs that inhibit the human cardiac
delayed rectifier potassium current may lead to prolongation of the cardiac QT interval and …

Pharmacokinetics of concentrated naloxone nasal spray for opioid overdose reversal: Phase I healthy volunteer study

R McDonald, U Lorch, J Woodward, B Bosse… - …, 2018 - Wiley Online Library
Background and Aims Take‐home naloxone can prevent death from heroin/opioid overdose,
but pre‐provision is difficult because naloxone is usually given by injection. Non‐injectable …

[HTML][HTML] Three steps to writing adaptive study protocols in the early phase clinical development of new medicines

U Lorch, M O'Kane, J Taubel - BMC Medical Research Methodology, 2014 - Springer
This article attempts to define terminology and to describe a process for writing adaptive, early
phase study protocols which are transparent, self-intuitive and uniform. It provides a step …

[HTML][HTML] Phase 1/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial

…, J Harambat, WG van't Hoff, U Lorch… - Clinical Journal of the …, 2021 - journals.lww.com
Background and objectives In the rare disease primary hyperoxaluria type 1, overproduction
of oxalate by the liver causes kidney stones, nephrocalcinosis, kidney failure, and systemic …

Safety, Tolerability, Pharmacokinetics, and Antimalarial Activity of the Novel Plasmodium Phosphatidylinositol 4-Kinase Inhibitor MMV390048 in Healthy Volunteers

…, S Chalon, JS McCarthy, U Lorch… - Antimicrobial agents …, 2020 - Am Soc Microbiol
MMV390048 is a novel antimalarial compound that inhibits Plasmodium
phosphatidylinositol-4-kinase. The safety, tolerability, pharmacokinetic profile, and antimalarial …

Thorough QT study of the effect of intravenous amisulpride on QTc interval in Caucasian and Japanese healthy subjects

…, G Ferber, G Fox, S Fernandes, U Lorch… - British journal of …, 2017 - Wiley Online Library
Aim The D 2 /D 3 antagonist amisulpride has shown promising efficacy against postoperative
nausea and vomiting (PONV) at low doses. We investigated whether intravenous …